Nature nanotechnologyMar 19, 2026

Lipid nanoparticles linked to inactive drug forms for combined mRNA cancer immunotherapy

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

A prodrug lipid nanoparticle co-delivering IL-12 mRNA and an IDO inhibitor produced strong antitumor immune effects in a mouse colon cancer model.

Evidence

This was a formulation and preclinical mouse study testing prodrug ionizable lipid nanoparticles in transfection assays and a subcutaneous colon cancer model with primary and distal tumors.

Caveat

The evidence is limited to platform experiments and mouse tumors, so it does not establish safety or efficacy in human cancer.

Simplified

Regulating T cell phenotypes between activation and exhaustion remains a significant challenge for messenger RNA-based cancer immunotherapy. A potential approach to improve anti-cancer T cell activity is to co-deliver interleukin-12 (IL-12), to stimulate effector T cells, and indoleamine 2,3-dioxygenase (IDO) inhibitor, to suppress T cell exhaustion. Here we design prodrug ionizable lipid nanoparticles (pLNPs), via a library of prodrug ionizable lipids (pILs), incorporating an intracellularly cleavable IDO inhibitor within the pIL structure and encapsulating IL-12 messenger RNA. The lead pIL shows enhanced mRNA transfection over a clinically utilized ionizable lipid, as well as strong immunomodulatory effects via release of the IDO inhibitor. In a subcutaneous colon cancer mouse model, pLNP drives complete regression of primary tumours by eliciting effector T cell infiltration while reducing exhaustion, induces a memory T cell response and stimulates a systemic immune response that allows for regression of distal tumours in this study. These results highlight the promise of pLNPs for small-molecule drug and mRNA combination cancer immunotherapy.